Wysowski DK, Swartz L (2005) Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002 - the importance of reporting suspected reactions. Arch Intern Med 165:1363–1369. https://doi.org/10.1001/archinte.165.12.1363

Article  PubMed  Google Scholar 

Hay M, Thomas DW, Craighead JL et al (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 32:40–51. https://doi.org/10.1038/nbt.2786

Article  CAS  PubMed  Google Scholar 

Ward RA, Fawell S, Floc’h N et al (2021) Challenges and opportunities in Cancer Drug Resistance. Chem Rev 121:3297–3351. https://doi.org/10.1021/acs.chemrev.0c00383

Article  CAS  PubMed  Google Scholar 

Lynch S, Pridgeon CS, Duckworth CA et al (2019) Stem cell models as an in vitro model for predictive toxicology. Biochem J 476:1149–1158. https://doi.org/10.1042/bcj20170780

Article  CAS  PubMed  Google Scholar 

Prasad V, Mailankody S (2017) Research and development spending to bring a single Cancer drug to market and revenues after approval. JAMA Intern Med 177:1569–1575. https://doi.org/10.1001/jamainternmed.2017.3601

Article  PubMed  PubMed Central  Google Scholar 

Oleaga C, Bernabini C, Smith AST et al (2016) Multi-organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci Rep 6. https://doi.org/10.1038/srep20030

Sun D, Gao W, Hu H, Zhou S (2022) Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B 12:3049–3062. https://doi.org/10.1016/j.apsb.2022.02.002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 3:417–429. https://doi.org/10.1038/nrd1382

Article  CAS  PubMed  Google Scholar 

Newell DR, Burtles SS, Fox BW et al (1999) Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br J Cancer 81:760–768. https://doi.org/10.1038/sj.bjc.6690761

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lanz HL, Saleh A, Kramer B et al (2017) Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform. BMC Cancer 17:709. https://doi.org/10.1186/s12885-017-3709-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Norman GA (2019) Limitations of Animal studies for Predicting toxicity in clinical trials: is it time to Rethink Our Current Approach? JACC Basic Transl Sci 4:845–854. https://doi.org/10.1016/j.jacbts.2019.10.008

Article  PubMed  PubMed Central  Google Scholar 

Abbott A (2003) Cell culture: Biology’s new dimension. Nature 424:870–872. https://doi.org/10.1038/424870a

Article  CAS  PubMed  Google Scholar 

Tsai H-F, Trubelja A, Shen AQ, Bao G (2017) Tumor-on-a-chip: microfluidic models of tumor morphology, growth and microenvironment. J R Soc Interface 14. https://doi.org/10.1098/rsif.2017.0137

Lee SY, Lee BR, Lee J et al (2013) Microscale Diffusion measurements and Simulation of a Scaffold with a permeable strut. Int J Mol Sci 14:20157–20170. https://doi.org/10.3390/ijms141020157

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sung JH, Dhiman A, Shuler ML (2009) A combined pharmacokinetic-pharmacodynamic (PK-PD) model for Tumor Growth in the rat with UFT Administration. J Pharm Sci 98:1885–1904. https://doi.org/10.1002/jps.21536

Article  CAS  PubMed  Google Scholar 

Hwang H, Park J, Shin C et al (2013) Three dimensional multicellular cocultures and anticancer drug assays in rapid prototyped multilevel microfluidic devices. Biomed Microdevices 15:627–634. https://doi.org/10.1007/s10544-012-9733-9

Article  CAS  PubMed  Google Scholar 

Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4:359–365. https://doi.org/10.1038/nmeth1015

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsusaki M, Case CP, Akashi M (2014) Three-dimensional cell culture technique and pathophysiology. Adv Drug Deliv Rev 74:95–103. https://doi.org/10.1016/j.addr.2014.01.003

Article  CAS  PubMed  Google Scholar 

Zervantonakis IK, Kothapalli CR, Chung S et al (2011) Microfluidic devices for studying heterotypic cell–cell interactions and tissue specimen cultures under controlled microenvironments. Biomicrofluidics 5. https://doi.org/10.1063/1.3553237

Zhao Y, Kankala RK, Wang SB, Chen AZ (2019) Multi-organs-on-chips: toward Long-Term Biomedical investigations. Molecules 24:22. https://doi.org/10.3390/molecules24040675

Article  CAS  Google Scholar 

Esch MB, Ueno H, Applegate DR, Shuler ML (2016) Modular, pumpless body-on-a-chip platform for the coculture of GI tract epithelium and 3D primary liver tissue. Lab Chip 16:2719–2729. https://doi.org/10.1039/c6lc00461j

Article  CAS  PubMed  Google Scholar 

O’Brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267:5421–5426. https://doi.org/10.1046/j.1432-1327.2000.01606.x

Article  PubMed  Google Scholar 

Daeihamed M, Haeri A, Dadashzadeh S (2015) A simple and sensitive HPLC method for fluorescence quantitation of Doxorubicin in Microvolume plasma: applications to pharmacokinetic studies in rats. Iran J Pharm Res 14:33–42

CAS  PubMed  PubMed Central  Google Scholar 

Monolix version 2024R1 (2024) Antony, France: Lixoft SAS

Arnold RD, Slack JE, Straubinger RM (2004) Quantification of doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectrometry. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE. SCIENCES 808:141–152. https://doi.org/10.1016/j.jchromb.2004.04.030

Article  CAS  Google Scholar 

Daeihamed M, Haeri A, Ostad SN et al (2017) Doxorubicin-loaded liposomes: enhancing the oral bioavailability by modulation of physicochemical characteristics. NANOMEDICINE 12:1187–1202. https://doi.org/10.2217/nnm-2017-0007

Article  CAS  PubMed  Google Scholar 

Al-Abd AM, Kim NH, Song SC et al (2009) A simple HPLC method for doxorubicin in plasma and tissues of nude mice. Arch Pharm Res 32:605–611. https://doi.org/10.1007/s12272-009-1417-5

Article  CAS  PubMed  Google Scholar 

van Asperen J, van Tellingen O, Beijnen JH (1998) Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. J Chromatogr B-ANALYTICAL Technol BIOMEDICAL LIFE Sci 712:129–143. https://doi.org/10.1016/S0378-4347(98)00165-0

Article  CAS  Google Scholar 

Alvarez-Cedron L, Sayalero ML, Lanao JM (1999) High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE. SCIENCES 721:271–278. https://doi.org/10.1016/S0378-4347(98)00475-7

Article  CAS  Google Scholar 

Kummerle A, Krueger T, Dusmet M et al (2003) A validated assay for measuring doxorubicin in biological fluids and tissues in an isolated lung perfusion model: matrix effect and heparin interference strongly influence doxorubicin measurements. J Pharm Biomed Anal 33:475–494. https://doi.org/10.1016/S0731-7085(03)00300-5

Article  CAS  PubMed  Google Scholar 

Shah M, Bourner L, Ali S et al (2018) HPLC method development for quantification of doxorubicin in cell culture and placental perfusion media. Separations 5. https://doi.org/10.3390/separations5010009

Ricciarello R, Pichini S, Pacifici R et al (1998) Simultaneous determination of epirubicin, doxorubicin and their principal metabolites in human plasma by high-performance liquid chromatography and electrochemical detection. J Chromatogr B 707:219–225. https://doi.org/10.1016/S0378-4347(97)00610-5

Article  CAS  Google Scholar 

Choi C-H (2005) ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their